Founded in 2006, Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye.
The foundation of Ocular Therapeutix's pipeline is based on its proprietary, bioresorbable hydrogel technology that uses polyethylene glycol, or PEG, as a key component. The most advanced product candidate, currently in Phase 3 clinical development, is a drug-eluting intracanalicular depot containing the steroid dexamethasone for the treatment of ocular inflammation and pain following cataract surgery. Ocular also is evaluating a sustained released prostaglandin analog that can deliver treatment up to 90 days for the reduction of intraocular pressure for patients with glaucoma or ocular hypertension. All product candidates in the development pipeline are designed to replace weeks or months of dosing using existing pharmaceuticals and biologics with as little as a single dose administration. Earlier-stage product candidates are focused on the treatment of allergic and bacterial conjunctivitis and the company is also investigating intravitreal injections for wet age-related macular degeneration (AMD).
In January 2014, Ocular's ReSure® Sealant became the first and only FDA-approved sealant for ophthalmic use. The ReSure® Sealant is indicated for prevention of postoperative fluid egress from clear corneal incisions following cataract surgery is, one of the most commonly performed surgeries in the U.S. with about 3.5 million procedures performed annually.